Spots Global Cancer Trial Database for A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Official Title: A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Study ID: NCT00445458
Study Description
Brief Summary: The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scripps, Clinic General, La Jolla, California, United States
Moores UC San Diego Cancer Center, La Jolla, California, United States
Sharp Memorial Hospital, San Diego, California, United States
Boston University Medical Center, Boston, Massachusetts, United States
Mid-Michigan Physicians-HOS Division, Lansing, Michigan, United States
Oncology Care Associates, Saint Joseph, Michigan, United States
Columbia University Medical Center, New York, New York, United States
CTRC at The University of Texas Health Science Center, San Antonio, Texas, United States
Institut Jules Bordet Unite du Chimiotherapie, Brussels, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
AZ Groeninge Campus Maria's Voorzienigheid (MV), Kortrijk, , Belgium
Oncologisch Centrum GZA - Location St Augustinus, Wilrijk, , Belgium
Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, China
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Tianjin Cancer Hospital, TianJin, Tianjin, China
Tianjin Union Medicine Center Department of Oncology, Tianjin, Tianjin, China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, , China
Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, , China
UNIMED Medical Institute, Hong Kong, , Hong Kong
Department of Medicine, Queen Mary Hospital, Hong Kong, , Hong Kong
Department of Surgery Queen Mary Hospital, Hong Kong, , Hong Kong
Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, Maharashtra, India
M.M.F. Joshi Hospital & Ratna Memorial Hospital, Pune, Maharashtra, India
Tata Memorial Hospital, Mumbai, Parel, India
Birla Cancer Centre, S.M.S. Medical College & Hospital, Jaipur, Rajasthan, India
Yonsei University Health System - Severance Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, , Korea, Republic of
Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera, Oddzial Onkologii, Krakow, , Poland
Oddzial Chemioterapii Centrum Onkologii Ziemii Lubelskiej, Lublin, , Poland
City Multifield Clinical Hospital #4 Department of chemotherapy, Dnipropetrovs'k State Medical Academy, Chair of Oncology and Medical Radiology, Dnipropetrovsk, , Ukraine
State Oncological Regional Treatment and Diagnostic Center Department of chemotherapy, Lviv, , Ukraine
Contact Details
Name: Puma
Affiliation: Biotechnology
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
